| Fenofibrate Therapy and Change of Renal Function: Management, what and How? |
|
Sang-Hyun Kim |
|
Department of Internal Medicine, Seoul National University College of Medicine; Cardiovascular Center, SMG-SNU Seoul Boramae Medical Center, Seoul, Korea |
| Fenofibrate 투여와 신장 기능의 변화: 무엇을 어떻게 고려해야 할까 |
|
김상현 |
|
서울대학교 의과대학 내과학교실, 보라매병원 심혈관센터 |
Correspondence:
Sang-Hyun Kim, Tel: +82-2-870-3864, Fax: +82-2-870-3866, Email: shkimmd@snu.ac.kr
|
|
|
|
|
| This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Abstract |
|
Fenofibrate is one of PPAR-α (peroxisome proliferator activated receptor alpha) agonists. Fenofibrate decreases effectively triglyceride and increases high density lipoprotein cholesterol level through the effect on lipoprotein lipase, hepatic production and degradation of lipoproteins. Fenofibrate was recommended as the drug for hypertriglyceridemia treatment in European guideline released in 2011. But American heart association guideline in 2013 did not recommend non-statin therapy including fibrate for the prevention of atherosclerotic cardiovascular disease. But fenofibrate is still considered as the important drug for the management of atherogenic dyslipidemia especially in patients with metabolic syndrome and diabetes to reduce the residual risk after statin therapy from the evidence of many studies. Fibrates including bezafibrate, gemfibrozil, and fenofibrate increased serum creatinine level in several studies. But the mechanism of change in renal function is not clear till now. And the reversibility of renal function with drug discontinuation is dependent on the kinds of fibrate. Fenofibrate increased serum creatinine level, decreased albuminuria and renal function was reversible with the drug discontinuation in large clinical trials. In these days renal function change with fenofibrate therapy in Korean patients with hypertriglyceridemia was investigated. Fenofibrate treatment for 2 months increased serum creatinine level significantly and old age was associated with the change of renal function in multivariate analysis. Short-term therapy significantly increased serum creatinine level even within normal range, and this change may be important in some groups especially old age. (Korean J Med 2014;86:698-701) |
| Key Words:
Fenofibrate; Creatinine; Glomerular filtration rate |
| 주제어:
페노피브레이트; 크레아티닌; 사구체 여과율 |
PDF Links
Full text via DOI
Download Citation
